Ramchandani R, Wang Y, Booth BP et al (2007) The role of SN-38 exposure UGT1A1*28
polymorphism, and baseline bilirubin level in predicting severe irinotecan activity. J Clin
Pharmacol 47:78–86
Saito YA, Camilleri M (2006) Clinical application of pharmacogenetics in gastrointestinal dis-
eases. Expert Opin Pharmacother 7:1857–1869
Schmalfuss F, Kolominsky-Rabas PL (2013) Personalized medicine in screening for malignant
disease: a review of methods and applications. Biomark Insights 8:9–14
Somma V, Ababneh H, Ababneh A et al (2013) The novel Crohn’s disease marker anti-GP2
antibody is associated with ileocolonic location of disease. Gastroenterol Res Pract
2013:683824. doi:10.1155/2013/683824
Tesˇija Kuna A (2013) Serological markers of inflammatory bowel disease. Biochem Med (Zagreb)
23(1):28–42
Weinshilboum RM, Sladek SL (1980) Mercaptopurine pharmacogenetics: monogenic inheritance
of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 32(5):651–662
Wen S, Velin D, Pan-Hammarstr€om Q et al (2007) Expression of Helicobacter pylori virulence
factors and associated expression profiles of inflammatory genes in the human gastric mucosa.
Infect Immun 75:5118–5126
Yen JL, McLeod HL (2007) Should DPD analysis be required prior to prescribing
fluorpyrimidines? Eur J Cancer 43:1011–1016
264 D. Sˇtimac and N. Franjic ́